Agree. Logically, if there was no potentially good data from the first 2 groups it would make no difference to the outcome if the patients in the 120 unit cohort know or not... as I said earlier, any delay in the release suggests they found something in the 52 week data for the first 2 groups. And the results from patient number 1 tells its really possible. That Phase 1 data has been released as a concession to the shareholders as a clue.
Ann: NTCELL and Parkinson's Clinical Trial Update, page-20
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.6¢ | $41.21K | 6.825M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 3056700 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 913000 | 5 |
View Market Depth
| Last trade - 15.36pm 27/09/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |